Anti-epileptic drugs and hepatitis C therapy: Real-world experience

被引:7
|
作者
Marcos-Fosch, Cristina [1 ]
Cabezas, Joaquin [2 ]
Crespo, Javier [2 ]
Buti, Maria [1 ,3 ]
机构
[1] Hosp Univ Vall dHebron, Internal Med Dept, Liver Unit, Barcelona, Spain
[2] Marques de Valdecilla Univ Hosp, Gastroenterol & Hepatol Dept, Santander, Spain
[3] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
关键词
D O I
10.1016/j.jhep.2021.05.040
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
引用
收藏
页码:984 / 985
页数:2
相关论文
共 50 条
  • [1] Anti-epileptic Drugs
    Howard, Paul
    Twycross, Robert
    Shuster, John
    Mihalyo, Mary
    Remi, Jan
    Wilcock, Andrew
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2011, 42 (05) : 788 - 804
  • [2] Anti-epileptic drugs and Seizure Freedom - a real world study with Natural Language AI
    Shek, Anthony
    Kraljevic, Zeljko
    Searle, Thomas
    Viana, Pedro
    Bruno, Elisa
    Teo, James
    Dobson, Richard
    Richardson, Mark
    EPILEPSIA, 2021, 62 : 166 - 167
  • [3] The new anti-epileptic drugs
    Murphy, R
    IRISH MEDICAL JOURNAL, 1995, 88 (06) : 198 - 199
  • [4] Newer anti-epileptic drugs
    Aneja, Satinder
    Sharma, Suvasini
    INDIAN PEDIATRICS, 2013, 50 (11) : 1033 - 1040
  • [5] Discontinuation of anti-epileptic drugs
    JericoPascual, I
    MauriLlerda, JA
    REVISTA DE NEUROLOGIA, 1997, 25 (146) : 1603 - 1606
  • [6] ANTI-EPILEPTIC DRUGS AND DEVELOPMENT
    FREDERICH, A
    LYON MEDICAL, 1976, 235 (12): : 979 - 988
  • [7] EFFICACY OF ANTI-EPILEPTIC DRUGS
    PORTER, R
    ARCHIVES OF NEUROLOGY, 1981, 38 (11) : 734 - 734
  • [8] Newer anti-epileptic drugs
    Satinder Aneja
    Suvasini Sharma
    Indian Pediatrics, 2013, 50 : 1033 - 1040
  • [9] Commentary: real-world triple therapy experience treating hepatitis C virus
    Heron, T.
    Miller, M. H.
    Dillon, J. F.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (05) : 542 - 542
  • [10] Pharmacoeconomics of anti-epileptic drugs as adjunctive therapy for refractory epilepsy
    Simoens, Steven
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2010, 10 (03) : 309 - 315